# Validating novel DNA repair deficient cancer therapy targets and small molecule compounds

> **NIH NIH R41** · ANANEO THERAPEUTICS INC. · 2022 · $398,917

## Abstract

Abstract
Single-strand DNA repair (ssDR) is critical for preventing genomic catastrophe. AnaNeo Therapeutics was
founded by experts in DNA repair mechanisms. Extending our team’s previous fundamental ssDR studies we
analyzed >61,000 tumors for somatic mutations, generated isogenic mutant/wild-type cell line pairs, screened
two isogenic cell line pairs with small molecule libraries, performed computational and experimental synthetic
lethality (SL) screens and used state-of-the-art Schrodinger Maestro drug docking software to nominate small
molecule ssDR SL hits. Here in this Phase I STTR project we propose to validate candidate targets and small
molecule inhibitors. Overall, this study will nominate innovative ssDR SL precision therapy targets and small
molecule hits for lead optimization in future Phase II SBIR studies.

## Key facts

- **NIH application ID:** 10546636
- **Project number:** 1R41CA275627-01
- **Recipient organization:** ANANEO THERAPEUTICS INC.
- **Principal Investigator:** Richard Lipkin
- **Activity code:** R41 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $398,917
- **Award type:** 1
- **Project period:** 2022-09-01 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10546636

## Citation

> US National Institutes of Health, RePORTER application 10546636, Validating novel DNA repair deficient cancer therapy targets and small molecule compounds (1R41CA275627-01). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10546636. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*